Lu L, Zhan M, Li XY, Zhang H, Dauphars DJ, Jiang J, Yin H, Li SY, Luo S, Li Y, He YW. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Curr Res Immunol. 2022 Jun 3;3:118-127. doi: 10.1016/j.crimmu.2022.05.003. PMID: 35676925; PMCID: PMC9167882.

This review examines the limitations of current first-line therapies for hepatocellular carcinoma and explores the potential benefits and outcomes of incorporating immune checkpoint inhibitors into treatment. By summarizing the current landscape of clinically approved immune checkpoint inhibitor-based combination therapies across various cancer types, we identify future approaches that may help address the challenges of existing therapies.